Establishes Strategic Joint Venture to Pioneer ASEAN's Digital Securities Hub
JAKARTA, Indonesia, June 19, 2025 /PRNewswire/ -- Singapore-based Edena Capital Partners and its Korean technology subsidiary Group KS today announced their strategic entry into Indonesia's digital securities market, having successfully established joint venture "Edena Capital Nusantara" with prominent Indonesian partners to pioneer Security Token Offering (STO) exchange development across ASEAN's largest economy.
The joint venture was formalized through a signing ceremony in Jakarta today, with Wook Lee (CEO) and Chase S. Cho (Co-CEO) representing Edena Capital Partners, alongside Indonesian partners PT Dua Saudara Nusantara and PT Milkyverse Dunia Digital. The ceremony was attended by key stakeholders including Rendy Ronaldy Bimantara (CEO, PT Dua Saudara Nusantara), Yayang Ruzaldy (Co-Representative, PT Dua Saudara Nusantara), and Rob Clinton Kardinal (Representative, PT Milkyverse Dunia Digital).
Pioneering ASEAN's Digital Securities Transformation
"Having established our strong local partnership, we are now positioned to enter Indonesia's inaugural STO exchange sandbox program and build ASEAN's leading digital securities infrastructure," said Wook Lee, CEO of Edena Capital Partners. "This joint venture enables us to connect Indonesia's 270 million people to international capital markets while establishing the foundation for ASEAN's digital securities ecosystem. We're integrating this with our proven exchange operations in Cambodia and strategic partnerships in Malaysia."
Through Edena Capital Nusantara, the company will operate the "Edena Indonesia" STO exchange, cementing its position as the first international platform capturing Indonesia's first STO sandbox opportunity and leading ASEAN's digital securities evolution.
ASEAN Digital Securities Leadership Strategy
EDENA's Indonesia market entry strategy demonstrates regional advantages:
- Strategic Partnership: Joint venture with Indonesian market leaders
- Regional Hub Development: Positioning Indonesia as ASEAN's digital securities center
- Cross-Border Integration: Connecting Indonesia to broader ASEAN digital securities network
- Comprehensive Assets: Carbon credits and comprehensive tokenized asset offerings
The platform will prioritize carbon credit tokenization – aligning with President Jokowi's Green Recovery initiatives and Indonesia's 2030 carbon neutrality commitments, while building comprehensive digital securities capabilities establishing Indonesia as ASEAN's innovation hub.
Advanced Infrastructure for Regional Growth
Operating from Singapore with regulatory expertise across ASEAN jurisdictions, EDENA has developed STO infrastructure for multi-jurisdiction compliance. The hybrid blockchain architecture enables regulatory adherence and cross-border transactions across different frameworks.
EDENA's approach centers on building integrated infrastructure connecting regional markets. With global STO market projected at $2.4 trillion by 2030, the company's Indonesia entry positions it to lead ASEAN's digital securities transformation and establish regional digital finance leadership.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
EDENA ANNOUNCES INDONESIA DIGITAL SECURITIES MARKET ENTRY
|
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.
The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.
Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.
About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com
Investor Relations
ir@fieldmedicalinc.com
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.
The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.
Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.
About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com
Investor Relations
ir@fieldmedicalinc.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
